Gene:

COMT

catechol-O-methyltransferase

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

	Variant? (build 132)	Alternate Names ?	Drugs ?	Alleles ? (+ chr strand)	Function ?	Amino Acid? Translation
VA	rs13306278		Selective serotonin reuptake inhibitors	C > T	Not Available
CA VA	rs165599	c.*522G>A, g.3108931G>A, g.32519G>A, g.52529C>T	risperidone bupropion	G > A	Not Available
CA VA	rs4646316	c.465+310C>T, c.615+310C>T, g.27870C>T, g.3104282C>T	cisplatin	C > T	Not Available
VIP CA VA	rs4680	COMP: Val158Met, COMT:Val108Met, c.322G>A, c.472G>A, g.18331271G>A, g.27009G>A, g.3103421G>A, p.Val108Met, p.Val158Met	nicotine antipsychotics morphine lithium fluvoxamine	G > T G > C G > A	Missense	Val108Met
CA VA	rs9332377	COMT:rs9332377 A/G, c.466-367C>T, c.616-367C>T, g.3107842C>T, g.31430C>T, g.53618G>A	cisplatin	C > T	Not Available

Overview

Details

All alleles are displayed on the positive chromosomal strand.

Download Haplotype Data (CSV)

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

1. Estrogen Metabolism Pathway
   Estrogen metabolism in the liver.

2. Phenytoin Pathway, Pharmacokinetics
   Genes involved in the metabolism of phenytoin in the human liver cell.

External Pathways

Links to non-PharmGKB pathways.

1. Enzymatic degradation of dopamine by COMT - (Reactome via Pathway Interaction Database)
2. Enzymatic degradation of Dopamine by monoamine oxidase - (Reactome via Pathway Interaction Database)
3. Methylation - (Reactome via Pathway Interaction Database)

Publications related to COMT: 100

	Pharmacogenomics of the RNA world: structural RNA polymorphisms in drug therapy. Clinical pharmacology and therapeutics. 2011. Sadee W, et al. [Article:21289622@PubMed]
	Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. European journal of clinical pharmacology. 2011. Russo Roberta, et al. [Article:21069522@PubMed]
	Association of BDNF and COMT genotypes with cognitive processing of anti-smoking PSAs. Genes, brain, and behavior. 2011. Falcone Mary, et al. [Article:21883922@PubMed]
	Pharmacogenomics of cisplatin-induced ototoxicity. Pharmacogenomics. 2011. Mukherjea Debashree, et al. [Article:21787192@PubMed]
	Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia. Pharmacogenomics. 2011. Bitsios Panos, et al. [Article:21521027@PubMed]
	Analysis of 94 Candidate Genes and 12 Endophenotypes for Schizophrenia From the Consortium on the Genetics of Schizophrenia. The American journal of psychiatry. 2011. Greenwood Tiffany A, et al. [Article:21498463@PubMed]
	Economic impact of a genetic test for cisplatin-induced ototoxicity. The pharmacogenomics journal. 2011. Dionne F, et al. [Article:21502965@PubMed]
	Novel polymorphisms associated with tacrolimus trough concentrations: results from a multicenter kidney transplant consortium. Transplantation. 2011. Jacobson Pamala A, et al. [Article:21206424@PubMed]
	Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2010. Delorme Richard, et al. [Article:19676096@PubMed]
	Breaking Barriers in the Genomics and Pharmacogenetics of Drug Addiction. Clinical pharmacology and therapeutics. 2010. Ho M K, et al. [Article:20981002@PubMed]
	Pharmacogenetics of antidepressive treatment. European archives of psychiatry and clinical neuroscience. 2010. Zobel Astrid, et al. [Article:20047055@PubMed]
	Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenetics and genomics. 2010. Tchivileva Inna E, et al. [Article:20216107@PubMed]
	Genetic polymorphism of catechol-O-methyltransferase and cytochrome P450c17alpha in preeclampsia. Pharmacogenetics and genomics. 2010. Lim Ji Hyae, et al. [Article:20729792@PubMed]
	A current update on ADHD pharmacogenomics. Pharmacogenomics. 2010. Kieling Christian, et al. [Article:20235795@PubMed]
VA	Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 2010. McCarthy Michael J, et al. [Article:21047205@PubMed]
VA	Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. The pharmacogenomics journal. 2010. Ji Y, et al. [Article:20877297@PubMed]
	Variation in catechol-O-methyltransferase is associated with duloxetine response in a clinical trial for major depressive disorder. Biological psychiatry. 2009. Perlis Roy H, et al. [Article:19095219@PubMed]
	Pharmacogenetics of modafinil after sleep loss: catechol-O-methyltransferase genotype modulates waking functions but not recovery sleep. Clinical pharmacology and therapeutics. 2009. Bodenmann S, et al. [Article:19037200@PubMed]
	The consequence of concomitantly present functional genetic variants for the identification of functional genotype-phenotype associations in pain. Clinical pharmacology and therapeutics. 2009. Lötsch J, et al. [Article:18548001@PubMed]
	MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2009. Hilli Johanna, et al. [Article:19223155@PubMed]
VA	Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nature genetics. 2009. Ross Colin J D, et al. [Article:19898482@PubMed]
	Catechol O-methyltransferase pharmacogenomics: human liver genotype-phenotype correlation and proximal promoter studies. Pharmacogenetics and genomics. 2009. Zhang Jianping, et al. [Article:19641441@PubMed]
	Variants in COMT and spontaneous smoking cessation: retrospective cohort analysis of 925 cessation events. Pharmacogenetics and genomics. 2009. Breitling Lutz Philipp, et al. [Article:19584770@PubMed]
	Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics. 2009. Gupta Meenal, et al. [Article:19290789@PubMed]
	Genetic susceptibility to schizophrenia: role of dopaminergic pathway gene polymorphisms. Pharmacogenomics. 2009. Gupta Meenal, et al. [Article:19207030@PubMed]
	Variation in the COMT gene: implications for pain perception and pain treatment. Pharmacogenomics. 2009. Andersen Sonja, et al. [Article:19374521@PubMed]
	A common variant in DRD3 gene is associated with risperidone-induced extrapyramidal symptoms. The pharmacogenomics journal. 2009. Gassó P, et al. [Article:19506579@PubMed]
VA	Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. The pharmacogenomics journal. 2009. Fijal B A, et al. [Article:19451915@PubMed]
	Pharmacogenetics of morphine: Potential implications in sickle cell disease. American journal of hematology. 2008. Darbari Deepika S, et al. [Article:17722074@PubMed]
	Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. American journal of human genetics. 2008. Mill Jonathan, et al. [Article:18319075@PubMed]
VA	Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Molecular psychiatry. 2008. Bakker P R, et al. [Article:18180754@PubMed]
	Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nature genetics. 2008. Allen Nicole C, et al. [Article:18583979@PubMed]
	Association between the catechol-O-methyltransferase Val158Met polymorphism and cocaine dependence. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008. Lohoff Falk W, et al. [Article:18704099@PubMed]
	COMT Val108/158Met polymorphism and the modulation of task-oriented behavior in children with ADHD. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008. Sengupta Sarojini, et al. [Article:18580877@PubMed]
	Improvement of prepulse inhibition and executive function by the COMT inhibitor tolcapone depends on COMT Val158Met polymorphism. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2008. Giakoumaki Stella G, et al. [Article:18536698@PubMed]
VA	Association of COMT Val108/158Met genotype with smoking cessation. Pharmacogenetics and genomics. 2008. Munafò Marcus R, et al. [Article:18192898@PubMed]
	The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications. Pharmacogenetics and genomics. 2008. Bialecka Monika, et al. [Article:18698234@PubMed]
	Pharmacogenetic insights into codeine analgesia: implications to pediatric codeine use. Pharmacogenomics. 2008. Madadi Parvaz, et al. [Article:18781855@PubMed]
VA	Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biological psychiatry. 2007. Berrettini Wade H, et al. [Article:16876132@PubMed]
VA	Association of COMT Val108/158Met genotype with smoking cessation in a nicotine replacement therapy randomized trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2007. Johnstone Elaine C, et al. [Article:17548664@PubMed]
	Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain. 2007. Reyes-Gibby Cielito C, et al. [Article:17156920@PubMed]
	Interaction between serotonin transporter gene, catechol-O-methyltransferase gene and stressful life events in mood disorders. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2007. Mandelli Laura, et al. [Article:16756688@PubMed]
	Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. The pharmacogenomics journal. 2007. Molero P, et al. [Article:17363961@PubMed]
	Estrogens, enzyme variants, and breast cancer: a risk model. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006. Crooke Philip S, et al. [Article:16985022@PubMed]
VIP	Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase. Cellular and molecular neurobiology. 2006. Weinshilboum Richard M. [Article:16807786@PubMed]
	Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. Journal of clinical psychopharmacology. 2006. Nolan Karen A, et al. [Article:16702905@PubMed]
	Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. Journal of the National Cancer Institute. 2006. Rebbeck Timothy R, et al. [Article:16985250@PubMed]
	Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science (New York, N.Y.). 2006. Nackley A G, et al. [Article:17185601@PubMed]
VIP	Estrogen carcinogenesis in breast cancer. The New England journal of medicine. 2006. Yager James D, et al. [Article:16421368@PubMed]
VIP	Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Human genetics. 2005. Lee Seong-Gene, et al. [Article:15645182@PubMed]
	Breast cancer risk associated with genotype polymorphism of the catechol estrogen-metabolizing genes: a multigenic study on cancer susceptibility. International journal of cancer. Journal international du cancer. 2005. Cheng Ting-Chih, et al. [Article:15455371@PubMed]
	Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatric disease and treatment. 2005. Lotrich Francis E, et al. [Article:18568127@PubMed]
	COMT polymorphisms and anxiety-related personality traits. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2005. Stein Murray B, et al. [Article:15956988@PubMed]
	Genetic susceptibility of catechol-O-methyltransferase polymorphism in Japanese patients with breast cancer. Oncology reports. 2005. Inoue Hiroshi, et al. [Article:16077979@PubMed]
	The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patients. Pain. 2005. Rakvåg Trude Teoline, et al. [Article:15927391@PubMed]
	Association of catechol-O-methyltransferase with smoking cessation in two independent studies of women. Pharmacogenetics and genomics. 2005. Colilla Susan, et al. [Article:15900212@PubMed]
	Pharmacogenetics of antihypertensive drug responses. American journal of pharmacogenomics : genomics-related research in drug development and clinical practice. 2004. Schwartz Gary L, et al. [Article:15174896@PubMed]
	Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biological psychiatry. 2004. Weickert Thomas W, et al. [Article:15522252@PubMed]
VIP	COMT haplotypes suggest P2 promoter region relevance for schizophrenia. Molecular psychiatry. 2004. Palmatier M A, et al. [Article:15098000@PubMed]
VIP	Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Molecular psychiatry. 2004. Shield A J, et al. [Article:14966473@PubMed]
VIP	Variants in the catechol-o-methyltransferase (COMT) gene are associated with schizophrenia in Irish high-density families. Molecular psychiatry. 2004. Chen X, et al. [Article:15124004@PubMed]
VIP	The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2004. Bilder Robert M, et al. [Article:15305167@PubMed]
	Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics. 2004. Anttila Sami, et al. [Article:15115916@PubMed]
	Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. The American journal of psychiatry. 2004. Bertolino Alessandro, et al. [Article:15465976@PubMed]
	Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Therapeutic drug monitoring. 2004. de la Torre Rafael, et al. [Article:15228154@PubMed]
	Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics. 2003. Inada Toshiya, et al. [Article:12815736@PubMed]
	The role of genetic factors in the development of hyperhomocysteinemia. Clinical chemistry and laboratory medicine : CCLM / FESCC. 2003. Geisel Jürgen, et al. [Article:14656021@PubMed]
	Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2003. Illi Ari, et al. [Article:12729939@PubMed]
	Interactions between genetic polymorphism of cytochrome P450-1B1, sulfotransferase 1A1, catechol-o-methyltransferase and tobacco exposure in breast cancer risk. International journal of cancer. Journal international du cancer. 2003. Saintot Monique, et al. [Article:14520706@PubMed]
	Catechol-O-methyltransferase and monoamine oxidase A genotypes and drug response to conventional neuroleptics in schizophrenia. Journal of clinical psychopharmacology. 2003. Illi Ari, et al. [Article:14520117@PubMed]
	L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients. Journal of neural transmission (Vienna, Austria : 1996). 2003. Dousa M K, et al. [Article:12898345@PubMed]
	Genetic origins of anxiety in women: a role for a functional catechol-O-methyltransferase polymorphism. Psychiatric genetics. 2003. Enoch Mary-Anne, et al. [Article:12605099@PubMed]
	COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (New York, N.Y.). 2003. Zubieta Jon-Kar, et al. [Article:12595695@PubMed]
	Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. The pharmacogenomics journal. 2003. Yamanouchi Y, et al. [Article:14610521@PubMed]
VIP	A highly significant association between a COMT haplotype and schizophrenia. American journal of human genetics. 2002. Shifman Sagiv, et al. [Article:12402217@PubMed]
	Association between the COMT locus and obsessive-compulsive disorder in females but not males. American journal of medical genetics. 2002. Alsobrook John P, et al. [Article:11840516@PubMed]
	Cytochrome P450 CYP1B1 and catechol O-methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Archives of toxicology. 2002. Kocaba¿ Neslihan Aygün, et al. [Article:12415427@PubMed]
	Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biological psychiatry. 2002. Bilder Robert M, et al. [Article:12372660@PubMed]
	Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer cell. 2002. Yeoh Eng-Juh, et al. [Article:12086872@PubMed]
	Case-control study of dopamine transporter-1, monoamine oxidase-B, and catechol-O-methyl transferase polymorphisms in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2002. Goudreau John L, et al. [Article:12465073@PubMed]
	Combined COMT and GST genotypes and hormone replacement therapy associated breast cancer risk. Pharmacogenetics. 2002. Mitrunen Katja, et al. [Article:11773866@PubMed]
	Catechol O-methyltransferase genetic polymorphism in panic disorder. The American journal of psychiatry. 2002. Woo Jong-Min, et al. [Article:12359690@PubMed]
	Sexual dimorphism of the catechol-O-methyltransferase gene in narcolepsy is associated with response to modafinil. The pharmacogenomics journal. 2002. Dauvilliers Y, et al. [Article:11990384@PubMed]
	Polymorphic catechol-O-methyltransferase gene and breast cancer risk. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2001. Mitrunen K, et al. [Article:11401913@PubMed]
	Limited association between a catechol-O-methyltransferase (COMT) polymorphism and breast cancer risk in Japan. International journal of clinical oncology / Japan Society of Clinical Oncology. 2001. Hamajima N, et al. [Article:11706521@PubMed]
	Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan. Neuropsychobiology. 2001. Liou Y J, et al. [Article:11150892@PubMed]
	Relationship between the Val158Met polymorphism of catechol O-methyl transferase and breast cancer. Pharmacogenetics. 2001. Yim D S, et al. [Article:11434504@PubMed]
	Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 2001. Egan M F, et al. [Article:11381111@PubMed]
	Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatric genetics. 2001. Herken H, et al. [Article:11525417@PubMed]
	Confirmation of an excess of the high enzyme activity COMT val allele in heroin addicts in a family-based haplotype relative risk study. American journal of medical genetics. 2000. Horowitz R, et al. [Article:11054766@PubMed]
	Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biological psychiatry. 1999. Palmatier M A, et al. [Article:10459407@PubMed]
	Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer research. 1999. Huang C S, et al. [Article:10519398@PubMed]
	Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer research. 1998. Thompson P A, et al. [Article:9605753@PubMed]
	Low activity allele of catechol-o-methyltransferase gene and Japanese unipolar depression. Neuroreport. 1998. Ohara K, et al. [Article:9631418@PubMed]
	Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neuroscience letters. 1998. Ohmori O, et al. [Article:9535125@PubMed]
	High-activity catechol-O-methyltransferase allele is more prevalent in polysubstance abusers. American journal of medical genetics. 1997. Vandenbergh D J, et al. [Article:9259381@PubMed]
	An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer research. 1997. Lavigne J A, et al. [Article:9407957@PubMed]
	Catechol-O-methyltransferase Val158Met polymorphism: frequency analysis in Han Chinese subjects and allelic association of the low activity allele with bipolar affective disorder. Pharmacogenetics. 1997. Li T, et al. [Article:9352569@PubMed]
VIP	Molecular mechanisms of estrogen carcinogenesis. Annual review of pharmacology and toxicology. 1996. Yager J D, et al. [Article:8725388@PubMed]
	Catechol-O-methyltransferase activity: a determinant of levodopa response. Clinical pharmacology and therapeutics. 1980. Reilly D K, et al. [Article:7398195@PubMed]

LinkOuts

Common Searches

• Search BioCarta and KEGG Pathways at CGAP
• Search Reactome